Evidence map›Paper›PMID 39675132›Full record

ArticlePatient education and counseling2025

Clinical trial knowledge, discussion, and participation among cancer survivors: A HINTS-SEER study.

Erin O Wissler Gerdes, Sarah H Nash, Robin C Vanderpool, Erin L Van Blarigan, Angela L W Meisner, Nicole Senft Everson

Abstract read
In one paragraph

Article in Patient education and counseling, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Erin O Wissler GerdesDepartment of Epidemiology, College of Public Health, University of Iowa, Iowa City, IA, USA.
Sarah H NashDepartment of Epidemiology, College of Public Health, University of Iowa, Iowa City, IA, USA.
Robin C VanderpoolDivision of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD, USA.
Erin L Van BlariganDepartments of Epidemiology and Biostatistics, and Urology, University of California, San Francisco, CA, USA; Greater Bay Area Cancer Registry, University of California, San Francisco, CA, USA.
Angela L W MeisnerNew Mexico Tumor Registry, Comprehensive Cancer Center, University of New Mexico, Albuquerque, NM, USA.
Nicole Senft EversonDivision of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD, USA. Electronic address: nicole.everson@nih.gov.

Funding

Development of Small Area Interactive Risk Maps for Cancer Control EffortsU01CA258400 · NCI · UNIVERSITY OF IOWA · PI OLESON, JACOB · 2022 to 2024
$950k
Intramural NIH HHS Z99 CA999999NCI NIH HHS HHSN261201800009CNCI NIH HHS HHSN261201800009INCI NIH HHS HHSN261201800014CNCI NIH HHS HHSN261201800014INCI NIH HHS HHSN261201800015CNCI NIH HHS HHSN261201800015INCI NIH HHS HHSN261201800032CNCI NIH HHS HHSN261201800032INCI NIH HHS U01 CA258400
6 · The paper itself

Abstract

objectivesClinical trial knowledge and discussions about clinical trials with healthcare providers contribute to clinical trial participation and clinical trial representation. This study explored 1) the association of patient-provider communication with clinical trial knowledge, 2) how patient-provider communication impacts the associations of demographic and clinical factors with clinical trial knowledge, and 3) motivations for clinical trial participation among people with a history of cancer.

methodsCross-sectional data from the 2021 Health Information National Trends Survey-Surveillance, Epidemiology, and End Results (HINTS-SEER) study included 1201 adult cancer survivors recruited from three SEER registries. Multivariable logistic regression models estimated adjusted associations of sociodemographic and clinical characteristics with clinical trial knowledge (none, a little bit/a lot) with and without the inclusion of clinical trial discussion with a healthcare provider (yes, no).

resultsApproximately three-quarters of cancer survivors reported having at least "a little" knowledge about clinical trials, though only 15 % reported having discussed clinical trials with their provider. Those who reported patient-provider communication about clinical trials had 8.71 times higher odds of having some clinical trial knowledge. In multivariable logistic regression, odds of knowing at least a little bit about clinical trials were lower among adults without a college degree and among Hispanic and Non-Hispanic Asian (versus Non-Hispanic White) adults. Associations of demographic factors with clinical trial knowledge were not impacted by the inclusion of patient-provider discussion in the model. Top motivations for clinical trial participation were helping other people, new treatment, and getting better. CONCLUSION/PRACTICE IMPLICATIONS: There is a need to ensure information about clinical trials is provided to all people with cancer and to facilitate high quality communication between patients and providers about clinical trials.

Indexed as

Cancer SurvivorsClinical Trials as TopicCommunicationHealth Knowledge, Attitudes, PracticeNeoplasmsPatient ParticipationPhysician-Patient RelationsAdultAgedCross-Sectional StudiesFemaleHumansMaleMiddle AgedMotivationSEER ProgramCancer survivorClinical trialsPatient-provider communication

Identifiers

PMID39675132
PMCPMC12754847

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.